Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer
Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer
复制标题
DOI：
10.3892/etm.2015.2743
复制
发表时间：
2015-11-01
影响因子：
2.7
通讯作者：
Tian, Xing-Song
中科院分区：
文献类型：
--
作者：
Li, Wen-Lei;Zhang, Yang;Tian, Xing-Song
本研究旨在探讨乳腺癌中S100A4的表达与新辅助化疗疗效的相关性。共有 65 名浸润性乳腺癌患者接受了 TAC 方案的新辅助化疗。采用免疫组化两步法检测治疗前、化疗2个周期后、化疗4个周期后S100A4的表达情况。采用Miller and Payne (MP)分级系统对化疗进行病理学评价，并探讨其与治疗期间和治疗后S100A4表达变化的相关性。新辅助化疗前与化疗后4个周期S100A4表达差异有统计学意义(P<0。05)。 S100A4表达强度及变化与新辅助化疗疗效呈正相关（r=0.259，P
The aim of this study was to investigate the correlation between the expression of S100A4 and the efficacy of neoadjuvant chemotherapy in breast cancer. A total of 65 patients with invasive breast cancer were treated with neoadjuvant chemotherapy using the TAC regimen. The expression of S100A4 was detected by an immunohistochemical two-step method prior to treatment, after 2 cycles of chemotherapy and after 4 cycles of chemotherapy. Pathological evaluations of the chemotherapy were performed using the Miller and Payne (MP) grading system and their correlation with the changes of S100A4 expression during and after the treatment were explored. Between pre-neoadjuvant chemotherapy and 4 cycles post-chemotherapy, there was a significant difference in the expression of S100A4 (P0.05). The intensity and changes of S100A4 expression were positively correlated with the efficacy of neoadjuvant chemotherapy (r=0.259, P